Intrinsiqq
Candel Therapeutics Inc. logo

Candel Therapeutics Inc. Insider Trading

CADL

Compare
Last 12 months

Insiders bought $3M and sold $3.55M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market
−551K
1 buy · 4 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
1 / 3
executives and directors
Last open-market buy
Feb 2026
Feb 23, 2026

Get an email when CADL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 10 – 1110b5-1 plan
    Paul Peter Tak
    Chief Executive Officer · sold 280,245 at avg $11.28
    $3.16M
    71% of stake
  • Aug 1710b5-1 plan
    Seshu Tyagarajan
    Chief Technology Officer · sold 7,000 at $12.00
    84K
    8.3% of stake
  • Jun 2910b5-1 plan
    Seshu Tyagarajan
    Chief Technology Officer · sold 7,000 at $10.02
    70K
    7.7% of stake
  • Jun 2910b5-1 plan
    Francesca Barone
    Chief Scientific Officer · sold 23,447 at $10.06
    236K
    23% of stake
  • Feb 23
    Paul B Manning
    Director · bought 550,458 at $5.45
    $3M
    11% of stake
  • Jul 28, 202510b5-1 plan
    William Garrett Nichols
    Chief Medical Officer · sold 937 at $6.98
    7K
    1.8% of stake
  • Jun 30, 202510b5-1 plan
    William Garrett Nichols
    Chief Medical Officer · sold 781 at $5.04
    4K
    1.5% of stake
  • Mar 18, 2025 – Mar 19, 202510b5-1 plan
    Paul Peter Tak
    Chief Executive Officer · sold 26,172 at avg $8.77
    230K
    10% of stake
  • Mar 18, 202510b5-1 plan
    William Garrett Nichols
    Chief Medical Officer · sold 45,316 at $8.76
    397K
    46% of stake
  • Mar 18, 202510b5-1 plan
    Francesca Barone
    Chief Scientific Officer · sold 32,146 at $8.76
    282K
    25% of stake
  • Mar 17, 202510b5-1 plan
    Seshu Tyagarajan
    Chief Technology Officer · sold 31,278 at $8.82
    276K
    27% of stake
  • Mar 17, 202510b5-1 plan
    Charles Schoch
    See Remarks · sold 5,000 at $8.83
    44K
    12% of stake
  • Jan 15, 2025No plan
    Seshu Tyagarajan
    Chief Technology Officer · sold 14,322 at $7.23
    104K
    13% of stake
  • Jan 15, 2025No plan
    Francesca Barone
    Chief Scientific Officer · sold 13,534 at $7.23
    98K
    11% of stake
  • Jan 15, 2025No plan
    Charles Schoch
    See Remarks · sold 9,511 at $7.23
    69K
    18% of stake
  • Jan 15, 2025No plan
    Paul Peter Tak
    Chief Executive Officer · sold 21,704 at $7.23
    157K
    7.9% of stake
  • Jan 15, 2025No plan
    William Garrett Nichols
    Chief Medical Officer · sold 10,428 at $7.23
    75K
    12% of stake
  • Jan 8, 2025No plan
    Francesca Barone
    Chief Scientific Officer · sold 13,673 at $8.22
    112K
    9.9% of stake
  • Jan 8, 2025No plan
    Charles Schoch
    See Remarks · sold 9,971 at $8.22
    82K
    16% of stake
  • Jan 8, 2025No plan
    Paul Peter Tak
    Chief Executive Officer · sold 21,172 at $8.22
    174K
    7.2% of stake
  • Jan 8, 2025No plan
    Seshu Tyagarajan
    Chief Technology Officer · sold 14,545 at $8.22
    120K
    12% of stake
  • Jan 8, 2025No plan
    William Garrett Nichols
    Chief Medical Officer · sold 10,799 at $8.22
    89K
    11% of stake
  • Dec 16, 2024
    Paul B Manning
    Director · bought 1,250,000 at avg $6.00
    $7.5M
    43% of stake
  • Nov 29, 2024No plan
    Seshu Tyagarajan
    Chief Technology Officer · sold 20,392 at $4.56
    93K
    14% of stake
  • Nov 29, 2024No plan
    Paul Peter Tak
    Chief Executive Officer · sold 48,847 at $4.56
    223K
    14% of stake
  • Nov 29, 2024No plan
    William Garrett Nichols
    Chief Medical Officer · sold 13,935 at $4.56
    64K
    12% of stake
  • Nov 29, 2024No plan
    Francesca Barone
    Chief Scientific Officer · sold 22,081 at $4.56
    101K
    14% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CADL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CADL

CompareIntrinsic value
VIVSVivoSim Labs, Inc.
$0.26-10.34%10
AIMAIM ImmunoTech Inc.
$0.11-4.50%25
KLRSKalaris Therapeutics, Inc.
$1.28-5.19%10
ATYRAtyr Pharma Inc.
$3.82+3.52%10
WINTWindtree Therapeutics Inc.
$0.00-33.33%10
INMBInmune Bio Inc.
$0.83-7.49%10
ZIVOZivo Bioscience Inc.
$5.50+0.00%0
ENZNViskase Holdings, Inc.
$4.35-1.14%0

Held by ETFs

CADL is in 16 US ETFs. The largest of them, with CADL's weight in each:

Spot a number that looks wrong? Check it in CADL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CADL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.